SCHEMBL30867751

SCHEMBL30867751

COC(=O)[C@@H]1CN(C(=O)OC(C)(C)C)CCN1Cc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.50
JAK2 O60674 1/20 0.47
JAK1 P23458 1/20 0.47
STS P08842 1/20 0.47
BCHE P06276 2/20 0.45
HTR6 P50406 2/20 0.45
BRD4 O60885 1/20 0.45
KDM4E B2RXH2 1/20 0.45
PKM P14618 1/20 0.45
USP30 Q70CQ3 1/20 0.45
ACHE P22303 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
SCD O00767 1/20 0.44
SCD5 Q86SK9 1/20 0.44
KEAP1 Q14145 1/20 0.43
NFE2L2 Q16236 1/20 0.43
OPRD1 P41143 1/20 0.43
OPRK1 P41145 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17913813 1.00 GPR119 (0.50) GPR119JAK2JAK1STSBCHE
SCHEMBL8568595 0.89 GPR119 (0.50) GPR119JAK2JAK1STSBCHE
SCHEMBL31740665 0.89 GPR119 (0.50) GPR119JAK2JAK1STSBCHE
SCHEMBL27619332 0.89 GPR119 (0.48) GPR119JAK2JAK1STSBRD4
SCHEMBL19132197 0.89 GPR119 (0.46) GPR119JAK2JAK1STSBRD4
SCHEMBL22800954 0.89 CYP3A4 (0.47) GPR119KDM4EHDAC1HDAC6
SCHEMBL27006693 0.88 GPR119 (0.49) GPR119JAK2JAK1STSBCHE
SCHEMBL4828897 0.87 GPR119 (0.48) GPR119JAK2JAK1STSBCHE
SCHEMBL4828906 0.87 GPR119 (0.48) GPR119JAK2JAK1STSBCHE
SCHEMBL29060414 0.86 GPR119 (0.53) GPR119JAK2JAK1STSBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132143-A1 HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF AMGEN INC. (US) 2026-05-14 US disclosed
US-20250368625-A1 PIPERAZINES Grünenthal GmbH (DE) 2025-12-04 US disclosed
EP-4598917-A1 HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF Amgen Inc. (US) 2025-08-13 EP disclosed
WO-2024076674-A1 HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF AMGEN INC. (US) 2024-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260132143-A1 HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF KRAS, NRAS, HRAS GPR119 2581/4885JAK2 465/4885JAK1 1616/4885
US-20250368625-A1 PIPERAZINES SSTR4, SSTR5, SSTR2 GPR119 46/4885JAK2 946/4885JAK1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.